Cost Analysis of Ropinirole versus Levodopa in the Treatment of Parkinson's Disease

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.21, Iss.2, 2003-01, pp. : 115-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson's Disease: Meta-Analysis of Randomized Controlled Trials

By Kulisevsky Jaime Pagonabarraga Javier

Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. : 147-161

Adis International

Access to resources Recommend Favorite

Ropinirole in the treatment of Parkinson’s disease

By Zesiewicz T.A. Hauser R.A.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 697-710

Informa Healthcare

Access to resources Recommend Favorite

The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson's Disease

Current Clinical Pharmacology, Vol. 2, Iss. 3, 2007-01 ,pp. : 234-243

Bentham Science Publishers

Access to resources Recommend Favorite

Ropinirole warranted versus levodopa/benserazide in PD

Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Ropinirole warranted versus levodopa/benserazide in PD

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 400, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite